Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation

Dialysis and Transplantation

Volumn 39, Issue 9, 2010, Pages 397-400

  Ridruejo, Ezequiel ^a,c   Adrover, Raúl ^b   Alonso, Cristina ^c,d   Mandó, Oscar G ^a   Silva, Marcelo O ^c  

^a CEMIC   (Argentina)

^b Hepatology Section   (Argentina)

^c UNIVERSIDAD AUSTRAL   (Argentina)

^d Fresenius Medical Care ^*  (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEPATITIS B; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

EID: 77957339492     PISSN: 00902934     EISSN: 19326920     Source Type: Journal    
DOI: 10.1002/dat.20485     Document Type: Article

References (26)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582-592.
3. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52-61.
4. Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial. 2008;21:440-446.
5. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.
6. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5:2913-2921. (Pubitemid 43923952)
7. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-662.
8. Grotz W, Gondolf K, Rasenack J, et al. Imminent liver failure in a hepatitis B positive renal allograft recipient: Successful therapy with interferon-alpha. Nephrol Dial Transplant. 1995;10:1932-1934.
9. Durlik M, Gaciong Z, Rowinska D, et al. Long-term results of treatment of chronic hepatitis B, C, and D with interferon alpha in renal allograft recipients. Transplant Int. 1998;11(suppl. 1):S135-S139.
10. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation. 2004;77:859-864. (Pubitemid 38436824)
11. Kamar N, Sandres-Saune K, Ribes D, et al. Effects of long-term lamivudine therapy in renal transplant recipients. J Clin Virol. 2004;31:298-303. (Pubitemid 39371064)
12. Thibaut D, Thibaut V, Bernard-Chabert B, et al. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2004;16:1367-1373. (Pubitemid 39642219)
13. Vigano M, Colombo M, Aroldi A, et al. Long-term lamivudine monotherapy in renal transplant recipients with hepatitis-B-related cirrhosis. Antiviral Ther. 2005;10:709-713. (Pubitemid 41376849)
14. De Silva HJ, Herath CA, Sheriff MHR. Lamivudine therapy for hepatitis B infection in postrenal transplant patients: results after 36 months follow-up. Liver Int. 2005;25:1074-1075.
15. Garcia A, Mazuecos A, González P, et al. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. Transplant Proc. 2005;37:1462-1463. (Pubitemid 40712083)
16. De Silva HJ, Dassanayake AS, Manamperi A, de Silva AP. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc. 2006;38:3118-3120. (Pubitemid 44737983)
17. Fontaine H, Vallet-Pichard A, Chaix ML, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation. 2005;80:1086-1092. (Pubitemid 41611932)
18. Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation. 2008;86:611-614.
19. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-2100. (Pubitemid 41623371)
20. Baraclude. Prescribing information. Available at: www.baraclude.com. Accessed November 10, 2009.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.
22. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020. (Pubitemid 43357805)
23. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010. (Pubitemid 43357804)
24. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAgpositive chronic hepatitis B. Gastroenterology. 2007;133:1437-1444.
25. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. Program and abstracts of the 44th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2009; Copenhagen, Denmark. Abstract 20.
26. Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy. 2009;29:1212-1227.